Deacon CF, Holst JJ. Linagliptin a xanthine based di-peptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type-2 diabetes. Expert Opin Investig Drugs 2011;19:133–40.Google Scholar
Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type-2 diabetes mellitus. Diabetes Obes Metab 2011;13:542–50.CrossrefWeb of SciencePubMedGoogle Scholar
Retlich S, Duval V, Ring A. Pharmacokinetics and pharmacodynamics of single intravenous doses (0.5–10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (B1 1356) in healthy male subjects. Clin Pharmacokinet 2010;49:829–40.Web of ScienceCrossrefGoogle Scholar
Fuchs H, Runge F, Held HD. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-glycoprotein mediated efflux. Eur J Pharm Sci 2012;45:533–8.CrossrefPubMedGoogle Scholar
Battestin V, Matsuda LK, Macedo GA. Fontesaplicacaoes de taninos tanasesemalimentos. Alim Nutrients Araraquara 2004;15:63–72.Google Scholar
Chia Y, Rajbanshi R, Calhoun C, Chin RH. Anti-neoplastic effects of gallic acid, a major component of toonasinensis leaf extract, on oral squamous carcinoma cells. Molecules 2010;15:8377–89.CrossrefGoogle Scholar
Amin MM, Arbid MS. Estimation of ellagic acid and repaglinide effects on insulin signaling, oxidative stress and inflammatory mediators of liver, pancreas, adipose tissue and brain in insulin resistant type 2 diabetic rats. Appl Physiol Nutr Metab 2017;42:181–92.CrossrefPubMedGoogle Scholar
Mali VR, Bodhankar SL, Mohan V, Thakurdesai PA. Subacute toxicity of ellagic acid in cholesterol fed hyperlipidemic rats. Toxicol Int 2008;15:91–5.Google Scholar
Athukuri BL, Neerati P. Enhanced oral bioavailability of diltiazem by the influence of gallic acid and ellagic acid in male Wistar rats. Involvement of CYP3A4 and P-glycoprotein inhibition. Phytother Res 2017;31:1441–8.CrossrefPubMedGoogle Scholar
Satish KB, Ramgopal A, Praveen K. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation. Drug Dev Ind Pharm 2017;43:932–8.PubMedWeb of ScienceCrossrefGoogle Scholar
Athukuri BL, Neerati P. Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition. Drug Metab Pers Ther 2016;31:229–34.PubMedGoogle Scholar
Sutton SC, Rinaldi MT, Vukovinsky KE. Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single pass intestinal perfusion model. AAPS Pharm Sci 2001;3:E25.Google Scholar
Bedada SK, Yellu NR, Neerati P. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats. Involvement of P-glycoprotein inhibition. Pharmacol Res 2016;68:338–43.Google Scholar
Stephens RH, O’Neill CA, Warhurst A, Carlson GL, Rowland M, Warhurst G. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001;296:584–91.PubMedGoogle Scholar
About the article
Published Online: 2019-06-29
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.